New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
08 March 2023 - 11:00PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company engaged in the discovery
and development of oral direct acting therapeutics for several
viral diseases, today announced six upcoming presentations at the
36th International Conference on Antiviral Research (ICAR), which
will take place March 13-17, 2023 in Lyon, France.
Presentation details are as follows:
Poster Number: 411Title: The
Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR), the HCV NS5B
and NS5A Inhibitors, Demonstrates Potent In Vitro Synergistic
Antiviral Activity and In Vivo Preclinical Safety Without Adverse
Interactions Session: Influenza, RSV, and Other
Respiratory Viruses SessionPoster Number:
537Title: Low Risk of Drug-Drug Interactions
(DDIs) for Bemnifosbuvir (BEM) Based Upon In Vitro Metabolism and
Transporter Interaction Studies Session:
Influenza, RSV, and Other Respiratory Viruses Session
Poster Number: 549Title:
Pharmacokinetics and Metabolism of [14C]-Bemnifosbuvir in Healthy
Male ParticipantsSession: Influenza, RSV, and
Other Respiratory Viruses Session
Oral Presentation Number:
019Title: Bemnifosbuvir (BEM, AT-527) a Potent
Inhibitor of SARS-CoV-2 Variants of Concern (VOC), and a Promising
Oral Antiviral with a High Resistance Barrier for Treatment of
COVID-19 and other Coronaviruses
InfectionsSession: Influenza, RSV, and Other
Respiratory Viruses Session
Oral Presentation Number:
046Title: AT-752 Targets Multiple Sites and
Activities on the Dengue Virus Replication Enzyme
NS5Session: SARS-CoV-2, Arboviruses, Other
Biothreat Viruses, andBroad Spectrum Antivirals II Session
Oral Presentation Number:
047Title: Five Cellular Enzymes in the Activation
Pathway of Bemnifosbuvir, a Drug-Candidate Against SARS-CoV-2
InfectionsSession: SARS-CoV-2, Arboviruses, Other
Biothreat Viruses, andBroad Spectrum Antivirals II Session
About Atea PharmaceuticalsAtea is a clinical
stage biopharmaceutical company focused on discovering, developing
and commercializing oral therapies to address the unmet medical
needs of patients with serious viral infections. Leveraging the
Company’s deep understanding of antiviral drug development,
nucleos(t)ide chemistry, biology, biochemistry and virology, Atea
has built a proprietary nucleos(t)ide prodrug platform to develop
novel product candidates to treat single stranded ribonucleic acid,
or ssRNA, viruses, which are a prevalent cause of serious viral
diseases. Atea plans to continue to build its pipeline of antiviral
product candidates by augmenting its nucleos(t)ide platform with
other classes of antivirals that may be used in combination with
its nucleos(t)ide product candidates. Currently, Atea is focused on
the development of orally-available antiviral agents for serious
viral infections, including severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and
hepatitis C virus (HCV). For more information, please visit
www.ateapharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding our expectations
surrounding the potential of our product candidates, including
bemnifosbuvir combination product candidates, and expectations
regarding our pipeline, including trial design and development
timelines. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the
uncertainty around and costs associated with the clinical
development of bemnifosbuvir as a potential treatment for COVID-19
and the combination of bemnifosbuvir and ruzasvir as a potential
treatment for HCV. These and other important factors discussed
under the caption “Risk Factors” in our Annual Report on Form 10-K
for the year ended December 31, 2022 and our other filings with the
SEC could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2024 to Jul 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Jul 2023 to Jul 2024